002424.SHE Guizhou Bailing Group Pharmaceutical Co Ltd
- Market cap
- CNY 6.21B
- P/E
- -
- P/B
- 1.93x
- ROE
- 1.3%
- Dividend yield
- 1.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002424.SHE undervalued?
Graham numberThe Graham number of Guizhou Bailing Group Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guizhou Bailing Group Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Guizhou Bailing Group Pharmaceutical Co Ltd yet.
Guizhou Bailing Group Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others. The company offers medicines in various forms, including tablets, tinctures, decoctions, capsules, granules, syrups, powders, pills, dews, pastes, and sprays, as well as wines and honey. Its products are used for cardiovascular, cerebrovascular, …
Full company profileGuizhou Bailing Group Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guizhou Bailing Group Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.21B | 2.59B | 3.14B | 2.85B | 3.09B | 3.11B | 3.54B | 4.26B | 3.83B | 3.05B | 1.88B |
| Gross Profit | 1.42B | 1.64B | 1.87B | 1.71B | 1.73B | 1.84B | 2.10B | 2.31B | 2.17B | 1.44B | 764M |
| Operating Income | 570M | 626M | 664M | 358M | 197M | 175M | 156M | -484M | 4.35M | 227M | 243M |
| EBITDA | 676M | 719M | 767M | 504M | 377M | 354M | 364M | -301M | 251M | 168M | 131M |
| Net Income | 482M | 526M | 563M | 283M | 152M | 118M | 138M | -415M | 33.6M | -104M | 42.6M |
| EPS | 0.34 | 0.37 | 0.39 | 0.20 | 0.11 | 0.08 | 0.10 | -0.30 | 0.02 | -0.07 | 0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 4.24B | 4.82B | 5.98B | 7.05B | 7.03B | 6.49B | 6.89B | 7.35B | 7.13B | 6.20B | 5.62B |
| Total Liabilities | 1.17B | 1.36B | 2.05B | 2.91B | 3.11B | 2.53B | 2.90B | 3.82B | 3.94B | 3.02B | 2.42B |
| Shareholders' Equity | 3.02B | 3.42B | 3.87B | 4.05B | 3.89B | 3.94B | 3.99B | 3.51B | 3.18B | 3.16B | 3.19B |
| Cash & Short-term Investments | 1.22B | 1.00B | 546M | 1.14B | 1.03B | 466M | 605M | 418M | 396M | 355M | 188M |
| Total Debt | 802M | 862M | 1.58B | 2.42B | 2.29B | 1.74B | 1.57B | 1.68B | 1.50B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 467M | 79.9M | -157M | 467M | 232M | 325M | 502M | 126M | 9.02M | 749M | - |
| Capital Expenditure | 159M | 145M | 129M | 122M | 90.0M | 426M | 68.5M | 104M | 42.0M | 125M | 27.0M |
| Free Cash Flow | 307M | -64.8M | -286M | 346M | 142M | -101M | 434M | 21.6M | -33.0M | 623M | -5.63M |
| Ratios | |||||||||||
| ROE | 16.0% | 15.4% | 14.6% | 7.0% | 3.9% | 3.0% | 3.5% | -11.8% | 1.1% | -3.3% | 1.3% |
| ROA | 11.4% | 10.9% | 9.4% | 4.0% | 2.2% | 1.8% | 2.0% | -5.6% | 0.5% | -1.7% | 0.8% |
| Net Profit Margin | 21.8% | 20.3% | 18.0% | 9.9% | 4.9% | 3.8% | 3.9% | -9.7% | 0.9% | -3.4% | 2.3% |
| Debt to Equity | 0.27x | 0.25x | 0.41x | 0.60x | 0.59x | 0.44x | 0.39x | 0.48x | 0.47x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guizhou Bailing Group Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 29, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 62.5M | 0.04 | - |
| 2024 | CNY 81.3M | 0.05 | 241.9% |
| 2023 | CNY 80.5M | 0.06 | - |
| 2022 | CNY 86.6M | 0.06 | 62.5% |
| 2021 | CNY 100M | 0.07 | 84.6% |
| 2020 | CNY 310M | 0.22 | 203.7% |
| 2019 | CNY 113M | 0.08 | 39.9% |
| 2018 | CNY 158M | 0.11 | 28.0% |
| 2017 | CNY 148M | 0.10 | 28.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on Oct 20, 2015.
Who owns Guizhou Bailing Group Pharmaceutical Co Ltd
- Insiders 33.19%
- Institutions 0.50%
- Public & others 66.31%
- Shares outstanding 1.39B
- Free float 1.12B
Guizhou Bailing Group Pharmaceutical Co Ltd company profile
- Company name
- Guizhou Bailing Group Pharmaceutical Co Ltd
- Ticker
- 002424.SHE
- ISIN
- CNE100000PY3
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 3, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,715
- Fiscal year end
- December
- Address
- No. 212, Xihang Road, Anshun, China, 561000
- Phone
- 86 851 3341 5126
- Website
- gzbl.com
About Guizhou Bailing Group Pharmaceutical Co Ltd
Guizhou Bailing Group Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells medicines in China. It operates through four segments: Industrial, Commerce, Medical institutions, and Others. The company offers medicines in various forms, including tablets, tinctures, decoctions, capsules, granules, syrups, powders, pills, dews, pastes, and sprays, as well as wines and honey. Its products are used for cardiovascular, cerebrovascular, cough, cold, gynecological, and pediatric areas. The company was incorporated in 1999 and is headquartered in Anshun, China.
Guizhou Bailing Group Pharmaceutical Co Ltd management
5- Mr. Min NiuGM & Director · born 1970
- Mr. Hongxing LiCFO & Accounting Supervisor · born 1985
- Mr. Pei ChenDeputy GM & Director · born 1985
- Mr. Yuan Zhen YuanExecutive Vice President · born 1969
- Mr. Yong JiangDirector · born 1968